Cellenkos is a clinical-stage biotechnology company focused on developing allogeneic, tissue-targeted immune T-regulatory cell (T-REG) therapies aimed at treating autoimmune diseases and inflammatory disorders. Their lead product, CK0801, is a first-in-class T-REG therapy derived from cord blood, which is clinically manufactured using Cellenkos' proprietary platform. This therapy is designed to replace defective T-REGs in patients, thereby restoring immune homeostasis and controlling diseases caused by T cell attacks, such as lupus, multiple sclerosis, and rheumatoid arthritis. Cellenkos emphasizes the importance of T-REGs in regulating the immune response and preventing excessive inflammation, which can lead to autoimmune conditions.

The unique technology behind Cellenkos' T-REGs involves extracting bona fide suppressor T-REG cells from healthy umbilical cord blood and utilizing their proprietary CRANE® platform to generate T-REGs that can expand within the body. These T-REGs are engineered to seek out inflammatory hotspots and adapt their suppressive functions to restore immune equilibrium. Key advantages of Cellenkos' T-REGs include their lack of plasticity, low immunogenicity, and surplus availability from public cord blood banks, which allows for large-scale production and storage of these cells. The company also maintains in-house cGMP manufacturing capabilities, ensuring control over the entire supply chain and facilitating the development of tailored therapeutic products for various inflammatory diseases.

United States

Cellenkos is an early stage clinical biotechnology company that focuses on umbilical cord blood derived T-regulatory cellular therapies for treating autoimmune diseases and inflammatory disorders. 

Cancer

Genetic Diseases

Hematologic Diseases

Immune System Diseases

Infectious Diseases

Lung Diseases

Lymphatic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Skin Diseases

Urogenital Diseases

Cellenkos

Bone Marrow Failure

CK0801

Biologics

Cell Therapies

Acute respiratory distress syndrome

COVID-19

CK0802

Amyotrophic lateral sclerosis

CK0803

Myelofibrosis

CK0804

Parkinson's disease

Graft-versus-host disease

CK0805

iPEX Syndrome

CK0806

T-cell lymphoma

CK0807

Lupus nephritis

CK0808

Texas

Therapeutic

Cellenkos

Company Details